Niamh Louise Pellegrini Nevro Corp (NVRO) insider trading activity

Niamh Louise Pellegrini is Chief Commercial Officer of NEVRO CORP. Currently has a direct ownership of 85,967 shares of NVRO, which is worth approximately $325,814. The most recent transaction as insider was on May 28, 2023, when has been sold 1,143 shares (Common Stock) at a price of $26.45 per share, resulting in proceeds of $30,232. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 86K

0% 3M change

0% 12M change

Total Value Held $325,814

Niamh Louise Pellegrini Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 28 2023	SELL Payment of exercise price or tax liability	$30,232 $26.45 p/Share	1,143 Reduced 1.31%	85,967 Common Stock
Mar 07 2023	BUY Grant, award, or other acquisition	-	39,282 Added 31.08%	87,110 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$67,266 $33.99 p/Share	1,979 Reduced 3.97%	47,828 Common Stock
Feb 28 2023	SELL Payment of exercise price or tax liability	$148,333 $31.44 p/Share	4,718 Reduced 8.65%	49,807 Common Stock
Aug 06 2022	SELL Payment of exercise price or tax liability	$205,635 $47.11 p/Share	4,365 Reduced 7.41%	54,525 Common Stock
Mar 02 2022	SELL Payment of exercise price or tax liability	$144,749 $71.27 p/Share	2,031 Reduced 3.33%	58,890 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	26,069 Added 29.97%	60,921 Common Stock
Aug 06 2021	SELL Payment of exercise price or tax liability	$522,741 $119.73 p/Share	4,366 Reduced 11.13%	34,852 Common Stock
Mar 10 2021	SELL Open market or private sale	$111,060 $148.08 p/Share	750 Reduced 1.88%	39,218 Common Stock
Mar 10 2021	BUY Exercise of conversion of derivative security	$48,712 $64.95 p/Share	750 Added 1.84%	39,968 Common Stock
Mar 02 2021	SELL Payment of exercise price or tax liability	$118,686 $168.11 p/Share	706 Reduced 1.77%	39,218 Common Stock
Mar 02 2021	BUY Grant, award, or other acquisition	-	9,596 Added 19.38%	39,924 Common Stock
Feb 10 2021	SELL Open market or private sale	$136,913 $182.55 p/Share	750 Reduced 2.41%	30,328 Common Stock
Feb 10 2021	BUY Exercise of conversion of derivative security	$48,712 $64.95 p/Share	750 Added 2.36%	31,078 Common Stock
Jan 11 2021	SELL Open market or private sale	$127,350 $169.8 p/Share	750 Reduced 2.41%	30,328 Common Stock
Jan 11 2021	BUY Exercise of conversion of derivative security	$48,712 $64.95 p/Share	750 Added 2.36%	31,078 Common Stock
Dec 10 2020	SELL Open market or private sale	$121,005 $161.34 p/Share	750 Reduced 2.41%	30,328 Common Stock
Dec 10 2020	BUY Exercise of conversion of derivative security	$48,712 $64.95 p/Share	750 Added 2.36%	31,078 Common Stock
Nov 10 2020	SELL Open market or private sale	$128,062 $170.75 p/Share	750 Reduced 2.41%	30,328 Common Stock
Nov 10 2020	BUY Exercise of conversion of derivative security	$48,712 $64.95 p/Share	750 Added 2.36%	31,078 Common Stock
Oct 22 2020	SELL Open market or private sale	$299,805 $165.0 p/Share	1,817 Reduced 5.65%	30,328 Common Stock
Oct 19 2020	SELL Open market or private sale	$155,000 $155.0 p/Share	1,000 Reduced 3.02%	32,145 Common Stock
Oct 13 2020	SELL Open market or private sale	$113,603 $151.47 p/Share	750 Reduced 2.21%	33,145 Common Stock
Oct 13 2020	BUY Exercise of conversion of derivative security	$48,712 $64.95 p/Share	750 Added 2.16%	33,895 Common Stock
Oct 09 2020	SELL Open market or private sale	$150,000 $150.0 p/Share	1,000 Reduced 2.93%	33,145 Common Stock

Also insider at

AFIB

Acutus Medical, Inc. Healthcare

Director

NLP